NCT05365438View on ClinicalTrials.gov

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

PHASE4RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
DyslipidemiasAtherosclerosisDiabetes Mellitus, Type 2
Interventions
DRUG

Omega 3-Atorvastatin

Atmeg 2 capsules with 1 pack of Omethyl cutielet

DRUG

Omega 3-Atorvastatin

Atmeg 2 capsules

DRUG

Atorvastatin-Ezetimibe

ezetimibe/atorvastatin 10/20 mg

Trial Locations (1)

13620

RECRUITING

SNUBH, Seongnam-si

All Listed Sponsors
collaborator

Korea United Pharm. Inc.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER